Evidence map›Paper›PMID 39772250›Full record

ArticleViruses2024

Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection.

Yulia Ammour, Eugenia Nikolaeva, Olesya Sagimbaeva, Pavel Shamsutdinov, Anastasia Astapenko, Yulia Zhelaeva, Marina Gavrilova, Olga Susova, Aleksey Mitrofanov, Ali Bekyashev and 4 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yulia AmmourI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.ORCID 0000-0003-0223-5738
Eugenia NikolaevaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.ORCID 0000-0003-2898-9722
Olesya SagimbaevaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.ORCID 0009-0003-2645-4799
Pavel ShamsutdinovI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Anastasia AstapenkoI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Yulia ZhelaevaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Marina GavrilovaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Olga SusovaN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Aleksey MitrofanovN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Ali BekyashevN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.ORCID 0000-0002-4160-9598
Tatiana NasedkinaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-2642-4202
Oxana SvitichI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Evgeny FaizuloevI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Vitaly ZverevI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.

Funding

Russian Science Foundation 22-15-00304
6 · The paper itself

Abstract

This study evaluates the oncolytic potential of the Moscow strain of reovirus against human metastatic melanoma and glioblastoma cells. The Moscow strain effectively infects and replicates within human melanoma cell lines and primary glioblastoma cells, while sparing non-malignant human cells. Infection leads to the selective destruction of neoplastic cells, mediated by functional viral replication. A positive correlation was identified between viral RNA accumulation and tumor cell death, with no replication observed in non-malignant cells. This study highlights the critical roles of cathepsins B, L, and S as mediators of the oncolytic process. The pharmacological inhibition of these enzymes significantly attenuated reovirus-induced cytotoxicity in melanoma and glioblastoma cells. Conversely, PKR production analysis revealed minimal activation in reovirus-infected tumor cells, suggesting that the hyperactivation of the RAS-signaling pathway and subsequent PKR inhibition do not directly contribute to the selective efficacy of reovirus. Moreover, infected tumor cells exhibited features of both apoptotic and non-apoptotic death, emphasizing the intricate mechanisms of reovirus-mediated oncolysis. These findings underscore the therapeutic promise of the Moscow strain of reovirus as a selective and potent oncolytic agent for targeting melanoma and glioblastoma cells.

Indexed as

CathepsinsGlioblastomaMelanomaOncolytic VirusesVirus ReplicationApoptosisCell Line, TumoreIF-2 KinaseHumansOncolytic VirotherapyReoviridaeCathepsinseIF-2 Kinasecathepsinsglioblastomamelanomaoncolytic virusesreovirus

Identifiers

PMID39772250
PMCPMC11680368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.